How India Exports Amikacin to the World

In the United States, Amikacin is approved for various indications, including severe bacterial infections. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for Amikacin, reflecting its established presence in the market. Notably, in October 2018, the FDA approved Arikayce, a liposomal inhalation suspension of Amikacin, for the treatment of Mycobacterium avium complex (MAC) lung disease in adults with limited treatment options. This approval was granted under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway), emphasizing the drug's importance in addressing unmet medical needs. The substantial number of active Indian exporters (327) supplying Amikacin to the U.S. market underscores the critical role of Indian pharmaceutical companies in meeting American healthcare demands.

Within the European Union, Amikacin is authorized for use in treating severe infections caused by susceptible strains of bacteria. The European Medicines Agency (EMA) has evaluated Amikacin-containing products, including Arikayce liposomal, which received marketing authorization in October 2020 for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by MAC in adults with limited treatment options. This approval highlights the EMA's commitment to facilitating access to essential medicines for rare conditions. Manufacturers exporting Amikacin to the EU and UK must comply with Good Manufacturing Practice (GMP) standards as outlined by the EMA and the UK's Medicines and Healthcare products Regulatory Agency (MHRA), ensuring product quality and patient safety.

Amikacin is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in treating severe bacterial infections. The 24th edition of the list, published in 2025, categorizes Amikacin under Access group antibiotics, recommended as a first-choice treatment for high-risk febrile neutropenia and severe pyelonephritis or prostatitis. This inclusion reflects the global consensus on Amikacin's importance in essential healthcare. Additionally, Amikacin is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality and efficacy across different regions.

In India, Amikacin is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. This classification mandates that Amikacin be dispensed only with a valid prescription from a registered medical practitioner, ensuring its appropriate use. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including Amikacin, to make them affordable and accessible. Manufacturers intending to export Amikacin are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

The patent landscape for Amikacin includes several key patents, particularly concerning specialized formulations. For instance, Insmed Incorporated holds multiple U.S. patents for Arikayce, a liposomal inhalation suspension of Amikacin, with expirations extending up to May 2035. These patents provide market exclusivity for specific formulations and uses, while the base compound, Amikacin, is available for generic production, allowing for broader access and competition in the market.

In March 2023, the European Medicines Agency (EMA) conducted a Periodic Safety Update Report Single Assessment (PSUSA) for Amikacin, leading to variations in product information to enhance safety and efficacy profiles. This assessment underscores the ongoing regulatory vigilance to ensure patient safety.

In October 2025, the EMA updated the marketing authorization for Arikayce liposomal, reflecting continued regulatory oversight and commitment to addressing rare pulmonary infections. These developments highlight the dynamic regulatory environment surrounding Amikacin and the importance of staying abreast of changes to maintain compliance and market access.

In summary, Amikacin's regulatory landscape is multifaceted, involving stringent oversight in major markets such as the United States, European Union, United Kingdom, and India. Its inclusion in the WHO Model List of Essential Medicines and recognition in major pharmacopoeias affirm its global significance. Indian pharmaceutical companies play a pivotal role in the global supply chain, necessitating adherence to diverse regulatory requirements to ensure continued market access and compliance.

Amikacin, an aminoglycoside antibiotic, is primarily produced in India, which has established itself as a significant manufacturer of Active Pharmaceutical Ingredients (APIs). However, the production of Amikacin APIs is heavily reliant on Key Starting Materials (KSMs) imported from China. This dependency poses a substantial risk, as any disruption in the supply of these KSMs can directly impact API production. Notably, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, highlighting the concentration risk in the supply chain.

Recent events have underscored this vulnerability. In July 2024, environmental regulations led to the shutdown of several Chinese chemical plants, causing significant supply chain disruptions for Indian pharmaceutical manufacturers. This resulted in increased prices and shortages of essential APIs, including those for antibiotics like Amikacin.

The export data from TransData Nexus indicates that the top five Indian exporters of Amikacin account for 47.7% of the total export value, with AVET LIFESCIENCES PRIVATE LIMITED alone contributing 15.2%. This concentration suggests a moderate risk, as disruptions affecting these key suppliers could significantly impact global Amikacin availability.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic production of critical APIs and reduce reliance on imports. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture essential molecules used in antibiotics, marking a significant step towards self-sufficiency.

Geopolitical tensions and shipping disruptions pose additional risks to the Amikacin supply chain. The Red Sea and Strait of Hormuz are critical maritime routes for Indian exports; any instability in these regions can lead to delays and increased shipping costs. Furthermore, escalating U.S.-China tensions have prompted regulatory bodies like the FDA to closely monitor potential drug shortages. In January 2025, the FDA issued guidance on reporting supply chain disruptions, emphasizing the importance of early notification to mitigate shortages.

• Diversify KSM Sourcing: Identify and qualify alternative suppliers for KSMs beyond China to reduce dependency and enhance supply chain resilience.

• Strengthen Domestic Production: Leverage government incentives like the PLI scheme to invest in domestic manufacturing capabilities for both KSMs and APIs.

• Enhance Supplier Collaboration: Develop strategic partnerships with multiple suppliers to ensure a more balanced and secure supply chain.

• Monitor Geopolitical Developments: Establish a dedicated team to track geopolitical events and assess their potential impact on the supply chain, enabling proactive risk management.

• Implement Robust Reporting Mechanisms: Adopt comprehensive reporting systems to promptly identify and address supply chain disruptions, aligning with regulatory guidelines.

RISK_LEVEL: MEDIUM